Moderna Is Ahead of Novavax As Phase 3 Clinical Study of mRNA-1273 Is Finishing While Phase 2 of NVX‑CoV2373 Clinical Test is Ongoing

Operation Warp Speed has helped Moderna financially to finish prolonged clinical studies of mRNA-1273. Now phase 3 of its clinical test is near the end while Moderna proceeds with talks on how many units of the vaccine it will manufacture for the world. Especially, Europe is preparing to order millions of COVID-19 vaccines from several companies. One of them is german based CureVac.

Novavax seems to conduct clinical studies of NVX-CoV2373 slower than its popular opponents. Part 2 of phase 2 of the clinical study is ongoing to neutralize the protein cover of COVID-19. Novavax didn’t receive any federal governments’ financial stimulus to speed up the trials.

As Novavax is struggling to finish the trials, the german CureVac may finish its trials for COVID-19 vaccines earlier than Moderna.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.